symbol,price,beta,volAvg,mktCap,lastDiv,range,changes,companyName,currency,cik,isin,cusip,exchange,exchangeShortName,industry,website,description,ceo,sector,country,fullTimeEmployees,phone,address,city,state,zip,dcfDiff,dcf,image,ipoDate,defaultImage,isEtf,isActivelyTrading,isAdr,isFund
PRME,7.7,0,363990,749212341,3.7249999999999996,6.11-21.73,0.7,"Prime Medicine, Inc.",USD,0001894562,,,NASDAQ Global Market,NASDAQ,Biotechnology,https://www.primemedicine.com,"Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address diseases by deploying gene editing technology. It offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. The company was incorporated in 2019 and is headquartered in Cambridge, Massachusetts.","Dr. Keith Michael Gottesdiener M.D., Ph.D.",Healthcare,US,175,617-564-0013,21 Erie Street,Cambridge,MA,02139,,0,https://financialmodelingprep.com/image-stock/PRME.png,2022-10-20,False,False,True,False,False
